Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature

References

• Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β 1-blocking agent in healthy volunteers. J Clin Ther Med. 2000;16(10):1531–1556.
   Google Scholar
• Summary of product characteristics of Rapibloc. Available from: https://mri.cts-mrp.eu/Human/Downloads/NL_H_3368_002_FinalSPC.pdf. Accessed February 27, 2020.
   Google Scholar
• AOP and AMOMED announce the launch of RAPIBLOC® (Landiolol) in Germany and Austria. Available from: https://www.amomed.com/aop-and-amomed-announce-the-launch-of-rapibloc-landiolol-in-germany-and-austria/?lang=en. 2017. Accessed February 27, 2020.
   Google Scholar
• Approval for Corebeta ^® for Injection 12. 5mg for Improvement of Image Quality in Coronary CT Angiography in Japan.
   Google Scholar
• Approval for Additional Indication of Onoact ® 50 for injection, Short-Acting Selective β 1 Blocker in Japan. Available from: https://www.ono.co.jp/eng/news/pdf/sm_cn131122.pdf. 2013. Accessed January 25, 2020..
   Google Scholar
• ONO. Submits Supplemental Application of ONOACT ® for Intravenous Infusion 50mg ・ 150mg, Short- Acting Selective β 1 Blocker for Indication of Ventricular Arrhythmia for a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan. Available from: https://www.ono.co.jp/eng/news/pdf/sm_cn180730_1.pdf. 2018. Accessed January 25, 2020..
   Google Scholar
• IGUCHI S, IWAMURA H, NISHIZAKI M, et al. Development of a highly cardioselective ultra short-acting BETA -blocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40(6):1462–1469. doi:10.1248/cpb.40.1462
   PubMed Web of Science ®Google Scholar
• Tsuchiya H, Mizogami M. Characteristic interactivity of landiolol, an ultra-short-acting highly selective β1-blocker, with biomimetic membranes: comparisons with β1-selective esmolol and non-selective propranolol and alprenolol. Front Pharmacol. 2013;4:150. doi:10.3389/fphar.2013.00150
   PubMed Web of Science ®Google Scholar
• Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth. 2001;48(10):985–989. doi:10.1007/BF03016588
   PubMed Web of Science ®Google Scholar
• Ikeshita K, Nishikawa K, Toriyama S, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22(4):361–366. doi:10.1007/s00540-008-0640-4
   PubMed Web of Science ®Google Scholar
• Shibata S, Okamoto Y, Endo S, Ono K. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci. 2012;118(2):255–265. doi:10.1254/jphs.11202FP
   PubMed Web of Science ®Google Scholar
• Tsunekawa K, Imawaka H, Yamamoto K, Shibakawa K, Hiraku S. Studies on the metabolic fate of ultra short acting BETA 1 blocker ONO-1101. (3) metabolism and protein binding. Drug Metab Pharmacokinet. 1997;12(1):31–41. doi:10.2133/dmpk.12.31
   Google Scholar
• Takahata T, Yasui-Furukori N, Sakamoto J, et al. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker. Drugs R D. 2005;6(6):385–394. doi:10.2165/00126839-200506060-00006
   PubMedGoogle Scholar
• He Q, Shi M, Liu X, et al. Determination of landiolol, an ultra-short-acting β1-receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;891–892:7–11. doi:10.1016/j.jchromb.2011.12.024
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang Q, Hua W, Zhou W, Huang M, Wang H. Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects. Drug Res (Stuttg). 2014;64(3):141–145. doi:10.1055/s-0033-1354368
   PubMedGoogle Scholar
• Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci. 2016;92:64–73. doi:10.1016/j.ejps.2016.06.022
   PubMed Web of Science ®Google Scholar
• Stix G, Wolzt M, Domanovits H, et al. Open-label two-dose pilot study of landiolol for the treatment of atrial fibrillation/atrial flutter in caucasian patients. Circ J. 2019;84(1):33–42. doi:10.1253/circj.CJ-19-0661
   PubMed Web of Science ®Google Scholar
• Ojima T, Iwahashi M, Nakamori M, et al. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg Today. 2014;44(5):839–847. doi:10.1007/s00595-013-0616-3
   PubMed Web of Science ®Google Scholar
• McCormack O, Zaborowski A, King S, et al. New-onset atrial fibrillation post-surgery for esophageal and junctional cancer: incidence, management, and impact on short- and long-term outcomes. Ann Surg. 2014;260(5):772–778. doi:10.1097/SLA.0000000000000960
   PubMed Web of Science ®Google Scholar
• Murthy SC, Law S, Whooley BP, Alexandrou A, Chu KM, Wong J. Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality. J Thorac Cardiovasc Surg. 2003;126(4):1162–1167. doi:10.1016/S0022-5223(03)00974-7
   PubMed Web of Science ®Google Scholar
• Yoshida T, Furukita Y, Yamamoto Y, et al. A randomized, open label study of the efficacy of prophylactic 24-h low-dose landiolol for atrial fibrillation in transthoracic esophagectomy. Esophagus. 2017;14(1):97–103. doi:10.1007/s10388-016-0553-5
   Web of Science ®Google Scholar
• Ojima T, Nakamori M, Nakamura M, et al. Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. Br J Surg. 2017;104(8):1003–1009. doi:10.1002/bjs.10548
   PubMed Web of Science ®Google Scholar
• Horikoshi Y, Goyagi T, Kudo R, Kodama S, Horiguchi T, Nishikawa T. The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: a randomized controlled clinical trial. J Clin Anesth. 2017;38:111–116. doi:10.1016/j.jclinane.2017.01.036
   PubMed Web of Science ®Google Scholar
• Balik M, Sander M, Trimmel H, Heinz G. Landiolol for managing post-operative atrial fibrillation. Eur Heart J Suppl. 2018;20(SupplA):A10–A14. doi:10.1093/eurheartj/sux036
   PubMedGoogle Scholar
• Kugo Y, Nishi H, Sekiya N, Yamada M, Takahashi T. Postoperative atrial fibrillation in patients who underwent thoracic aortic surgery. Kyobu Geka. 2018;71(2):83–87.
   PubMedGoogle Scholar
• Maisawa K, Yamazaki K, Ishitoya H, Shimamura Y. Effect of landiolol hydrochloride after off-pump coronary artery bypass. Asian Cardiovasc Thorac Ann. 2013;21(2):170–175. doi:10.1177/0218492312450865
   PubMedGoogle Scholar
• Fujiwara H, Sakurai M, Namai A, Kawamura T. Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery. Gen Thorac Cardiovasc Surg. 2009;57(3):132–137. doi:10.1007/s11748-008-0341-9
   PubMedGoogle Scholar
• Ito N, Tashiro T, Morishige N, et al. Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction. Heart Surg Forum. 2012;15(4):E189–E194. doi:10.1532/HSF98.20111152
   PubMed Web of Science ®Google Scholar
• Tanaka K. Effects of landiolol on hemodynamic improvement and prevention of atrial fibrillation in the perioperative period of off-pump coronary artery bypass grafting. Kyobu Geka. 2010;63(3):175–183.
   PubMedGoogle Scholar
• Wakamatsu H, Takase S, Sato Y, Seto Y, Kurosawa H, Yokoyama H. Effect of intra-operative low-dose infusion of landiolol hydrochloride on post-operative atrial fibrillation after off-pump coronary artery bypass grafting. Kyobu Geka. 2010;63(9):764–768.
   PubMedGoogle Scholar
• Nishi H, Sakaguchi T, Miyagawa S, et al. Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery. Heart Vessels. 2013;28(4):490–496. doi:10.1007/s00380-012-0263-4
   PubMed Web of Science ®Google Scholar
• Taenaka N, Kikawa S. Dose-dependent effect of landiolol, a new ultra-short-acting β(1)-blocker, on supraventricular tachyarrhythmias in postoperative patients. Clin Drug Investig. 2013;33(7):505–514. doi:10.1007/s40261-013-0093-x
   PubMed Web of Science ®Google Scholar
• Oka E, Iwasaki Y-K, Maru E, et al. Differential effectiveness of landiolol between atrial fibrillation and atrial flutter/atrial tachycardia patients with left ventricular dysfunction. Circ J. 2019;83(4):793–800. doi:10.1253/circj.CJ-18-1131
   PubMed Web of Science ®Google Scholar
• Sakai M, Jujo S, Kobayashi J, Ohnishi Y, Kamei M. Use of low-dose β(1)-blocker for sinus tachycardia in patients with catecholamine support following cardiovascular surgery: a retrospective study. J Cardiothorac Surg. 2019;14(1):145. doi:10.1186/s13019-019-0966-z
   PubMedGoogle Scholar
• Nagaoka E, Arai H, Tamura K, Makita S, Miyagi N. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2014;20(2):129–134. doi:10.5761/atcs.oa.12.02003
   PubMed Web of Science ®Google Scholar
• Fujii M, Bessho R, Ochi M, Shimizu K, Terajima K, Takeda S. Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. J Cardiovasc Surg (Torino). 2012;53(3):369–374.
   PubMed Web of Science ®Google Scholar
• Ogawa S, Okawa Y, Goto Y, Aoki M, Baba H. Perioperative use of a beta blocker in coronary artery bypass grafting. Asian Cardiovasc Thorac Ann. 2013;21(3):265–269. doi:10.1177/0218492312451166
   PubMedGoogle Scholar
• Sezai A, Minami K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011;141(6):1478–1487. doi:10.1016/j.jtcvs.2010.10.045
   PubMed Web of Science ®Google Scholar
• Sezai A, Nakai T, Hata M, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012;144(5):1241–1248. doi:10.1016/j.jtcvs.2012.06.042
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Sasaki Y, Hirai H, et al. Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. Int Heart J. 2012;53(6):359–363. doi:10.1536/ihj.53.359
   PubMed Web of Science ®Google Scholar
• Sezai A, Osaka S, Yaoita H, et al. Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: prevention of atrial fibrillation after cardiac surgery with landiolol hydrochloride for left ventricular dysfunction (PLATON) trial. J Thorac Cardiovasc Surg. 2015;150(4):957–964. doi:10.1016/j.jtcvs.2015.07.003
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Kitakaze M, Takamoto S, et al. Landiolol, an ultra-short-acting β1-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J. 2012;76(5):1097–1101. doi:10.1253/circj.cj-11-1332
   PubMed Web of Science ®Google Scholar
• Tamura T, Yatabe T, Yokoyama M. Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: a systematic review and meta-analysis. J Clin Anesth. 2017;42:1–6. doi:10.1016/j.jclinane.2017.07.009
   PubMed Web of Science ®Google Scholar
• Kiyokuni M, Konishi M, Sakamaki K, et al. Beneficial effect of early infusion of landiolol, a very short-acting beta-1 adrenergic receptor blocker, on reperfusion status in acute myocardial infarction. Int J Cardiol. 2016;221:321–326. doi:10.1016/j.ijcard.2016.07.076
   PubMed Web of Science ®Google Scholar
• Hoshi T, Sato A, Nishina H, et al. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study. J Cardiol. 2012;60(4):252–256. doi:10.1016/j.jjcc.2012.06.010
   PubMed Web of Science ®Google Scholar
• Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76(2):439–445. doi:10.1253/circj.CJ-11-0947
   PubMed Web of Science ®Google Scholar
• Park H, Otani H, Noda T, et al. Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention. Int J Cardiol. 2013;167(4):1547–1551. doi:10.1016/j.ijcard.2012.04.096
   PubMed Web of Science ®Google Scholar
• Hoole SP, Heck PM, Sharples L, et al. Cardiac remote ischemic preconditioning in coronary stenting (CRISP stent) study. a prospective, randomized control trial. Circulation. 2009;119(6):820–827. doi:10.1161/CIRCULATIONAHA.108.809723
   PubMed Web of Science ®Google Scholar
• Matsui Y, Suzuki A, Shiga T, Arai K, Hagiwara N. Effects of intravenous landiolol on heart rate and outcomes in patients with atrial tachyarrhythmias and acute decompensated heart failure: a single-center experience. Drugs - Real World Outcomes. 2019;6(1):19–26. doi:10.1007/s40801-019-0149-1
   PubMedGoogle Scholar
• Kobayashi S, Murakami W, Myoren T, et al. A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. Cardiology. 2014;127(2):105–113. doi:10.1159/000355312
   PubMed Web of Science ®Google Scholar
• Kiuchi S, Aikawa H, Hisatake S, et al. Efficacy of intravenous administration of landiolol in patients with acute heart failure and supraventricular tachyarrhythmia. J Clin Med Res. 2017;9(5):426–432. doi:10.14740/jocmr2954w
   PubMedGoogle Scholar
• Kobayashi S, Susa T, Tanaka T, et al. Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J. 2012;76(7):1646–1653. doi:10.1253/circj.CJ-12-0033
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Susa T, Ishiguchi H, et al. A low-dose β1-blocker in combination with milrinone improves intracellular Ca2+ handling in failing cardiomyocytes by inhibition of milrinone-induced diastolic Ca2+ leakage from the sarcoplasmic reticulum. PLoS One. 2015;10(1):e0114314–e0114314. doi:10.1371/journal.pone.0114314
   PubMed Web of Science ®Google Scholar
• Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77(4):908–916. doi:10.1253/circj.cj-12-1618
   PubMed Web of Science ®Google Scholar
• Wada Y, Aiba T, Tsujita Y, et al. Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction. J Arrhythmia. 2016;32(2):82–88. doi:10.1016/j.joa.2015.09.002
   PubMedGoogle Scholar
• Adachi T, Sato A, Baba M, et al. Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. Heart Vessels. 2014;29(4):464–469. doi:10.1007/s00380-013-0377-3
   PubMed Web of Science ®Google Scholar
• Calvin JE, Driedger AA, Sibbald WJ. An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy. Chest. 1981;80(5):579–586. doi:10.1378/chest.80.5.579
   PubMed Web of Science ®Google Scholar
• Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36(6):1701–1706. doi:10.1097/CCM.0b013e318174db05
   PubMed Web of Science ®Google Scholar
• Tang C, Yang J, Wu -L-L, Dong L-W, Liu M-S. Phosphorylation of β-adrenergic receptor leads to its redistribution in rat heart during sepsis. Am J Physiol Integr Comp Physiol. 1998;274(4):R1078–R1086. doi:10.1152/ajpregu.1998.274.4.R1078
   PubMed Web of Science ®Google Scholar
• Hunter JD, Doddi M. Sepsis and the heart. Br J Anaesth. 2010;104(1):3–11. doi:10.1093/bja/aep339
   PubMed Web of Science ®Google Scholar
• Shepherd RE, Lang CH, McDonough KH. Myocardial adrenergic responsiveness after lethal and nonlethal doses of endotoxin. Am J Physiol Circ Physiol. 1987;252(2):H410–H416. doi:10.1152/ajpheart.1987.252.2.H410
   PubMedGoogle Scholar
• Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med. 1995;333(16):1025–1032. doi:10.1056/NEJM199510193331601
   PubMed Web of Science ®Google Scholar
• Hayes MA, Timmins AC, Yau E, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically Ill patients. N Engl J Med. 1994;330(24):1717–1722. doi:10.1056/NEJM199406163302404
   PubMed Web of Science ®Google Scholar
• Schmittinger CA, Torgersen C, Luckner G, Schröder DCH, Lorenz I, Dünser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950–958. doi:10.1007/s00134-012-2531-2
   PubMed Web of Science ®Google Scholar
• Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA - J Am Med Assoc. 2013;310(16):1683–1691. doi:10.1001/jama.2013.278477
   PubMed Web of Science ®Google Scholar
• Wei C, Louis H, Schmitt M, et al. Effects of low doses of esmolol on cardiac and vascular function in experimental septic shock. Crit Care. 2016;20(1):1–10. doi:10.1186/s13054-016-1580-2
   PubMedGoogle Scholar
• Du W, Liu D, Long Y, Wang X. The β-blocker esmolol restores the vascular waterfall phenomenon after acute endotoxemia*. Crit Care Med. 2017;45(12):e1247–e1253. doi:10.1097/CCM.0000000000002721
   PubMed Web of Science ®Google Scholar
• Aboab J, Sebille V, Jourdain M, et al. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock. Intensive Care Med. 2011;37(8):1344–1351. doi:10.1007/s00134-011-2236-y
   PubMed Web of Science ®Google Scholar
• Seki Y, Jesmin S, Shimojo N, et al. Significant reversal of cardiac upregulated endothelin-1 system in a rat model of sepsis by landiolol hydrochloride. Life Sci. 2014;118(2):357–363. doi:10.1016/j.lfs.2014.04.005
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Iwasaka H, Maeda H, Noguchi T. Landiolol, an ultrashort-acting β1-adrenoceptor antagonist, has protective effects in an lps-induced systemic inflammation model. Shock. 2009;31(5):515–520. doi:10.1097/SHK.0b013e3181863689
   PubMed Web of Science ®Google Scholar
• Kiyonaga N, Moriyama T, Kanmura Y. Effects of landiolol in lipopolysaccharide-induced acute kidney injury in rats and in vitro. Shock. 2019;52(5):e117–e123. doi:10.1097/SHK.0000000000001306
   PubMed Web of Science ®Google Scholar
• Ogura Y, Jesmin S, Yamaguchi N, et al. Potential amelioration of upregulated renal HIF-1alpha-endothelin-1 system by landiolol hydrochloride in a rat model of endotoxemia. Life Sci. 2014;118(2):347–356. doi:10.1016/j.lfs.2014.05.007
   PubMed Web of Science ®Google Scholar
• Matsuishi Y, Jesmin S, Kawano S, et al. Landiolol hydrochloride ameliorates acute lung injury in a rat model of early sepsis through the suppression of elevated levels of pulmonary endothelin-1. Life Sci. 2016:166. doi:10.1016/j.lfs.2016.10.010.
   PubMed Web of Science ®Google Scholar
• Kurita T, Kawashima S, Morita K, Nakajima Y. Use of a short-acting β1 blocker during endotoxemia may reduce cerebral tissue oxygenation if hemodynamics are depressed by a decrease in heart rate. Shock. 2017;47(6):765–771. doi:10.1097/SHK.0000000000000795
   PubMed Web of Science ®Google Scholar
• Mathieu C, Desrois M, Kober F, et al. Sex-mediated response to the beta-blocker landiolol in sepsis: an experimental, randomized study. Crit Care Med. 2018;46(7):e684–e691. doi:10.1097/CCM.0000000000003146
   PubMed Web of Science ®Google Scholar
• Matyal R, Mahmood F, Panzica P, et al. Sex-related differences in outcome after high-risk vascular surgery after the administration of β-adrenergic-blocking drugs. J Cardiothorac Vasc Anesth. 2008;22(3):354–360. doi:10.1053/j.jvca.2007.12.021
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Hongo T, Sakamoto A, Ogawa R. Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol. Anesth Analg. 2005;100(1):294. doi:10.1213/01.ANE.0000140814.28118.6F
   PubMed Web of Science ®Google Scholar
• Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015;4(3):251–257. doi:10.5492/wjccm.v4.i3.251
   PubMedGoogle Scholar
• Unger M, Morelli A, Singer M, et al. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials. 2018;19(1):637. doi:10.1186/s13063-018-3024-6
   PubMedGoogle Scholar
• Wiest DB, Garner SS, Uber WE, Sade RM. Esmolol for the management of pediatric hypertension after cardiac operations. J Thorac Cardiovasc Surg. 1998;115(4):890–897. doi:10.1016/S0022-5223(98)70371-X
   PubMed Web of Science ®Google Scholar
• Tabbutt S, Nicolson SC, Adamson PC, et al. The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial. J Thorac Cardiovasc Surg. 2008;136(2):321–328. doi:10.1016/j.jtcvs.2007.09.086
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Fujita S, Shimao A, Futatani T, Hatasaki K. Successful treatment of neonatal idiopathic ventricular tachycardia with landiolol hydrochloride. Pediatr Int. 2019;61(10):1048–1050. doi:10.1111/ped.13969
   PubMed Web of Science ®Google Scholar
• Fujita S, Futatani T, Kubo T, et al. Virus myocarditis in a 1-month-old boy presenting as two types of paroxysmal supraventricular tachycardia. Pediatr Int. 2017;59(5):627–632. doi:10.1111/ped.13261
   PubMed Web of Science ®Google Scholar
• Miyake K, Fujita Y, Yoshizawa S, et al. Effects of landiolol on refractory tachyarrhythmia after total cavopulmonary connection: a retrospective, observational, cohort study. J Anesth. 2016;30(2):331–336. doi:10.1007/s00540-015-2119-4
   PubMed Web of Science ®Google Scholar
• Tokunaga C, Hiramatsu Y, Kanemoto S, et al. Effects of landiolol hydrochloride on intractable tachyarrhythmia after pediatric cardiac surgery. Ann Thorac Surg. 2013;95(5):1685–1688. doi:10.1016/j.athoracsur.2013.01.057
   PubMed Web of Science ®Google Scholar
• Yoneyama F, Tokunaga C, Kato H, et al. Landiolol hydrochloride rapidly controls junctional ectopic tachycardia after pediatric heart surgery. Pediatr Crit Care Med. 2018;19(8):713–717. doi:10.1097/PCC.0000000000001573
   PubMed Web of Science ®Google Scholar
• Sumitomo N, Horigome H, Miura M, et al. Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure using landiolol (HEARTFUL): a prospective, multicenter, uncontrolled clinical trial. J Cardiol. 2017;70(3):232–237. doi:10.1016/j.jjcc.2016.12.002
   PubMed Web of Science ®Google Scholar